biostudies-literatureUnknown12Morabito FThe present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no differeFrontiers in oncologyhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC9341470biostudies-literatureSurvival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsPMC9341470Zamagni EPalmieri SRossi EMartino EMusso MCavo MDe Stefano VFrigeri FTacchetti PMangiacavalli SCatalano LBruzzese ABringhen SPantani LVincelli ICascavilla NGalli MGamberi BOffidani MFalcone AMimmi SDi Raimondo FGentile MConticello CBarone MBoccadoro MMorabito FMusto PRia RBotta CTripepi GCurci PVigna EPavone VMendicino FReddiconto GNeri ABallanti SMele ADerudas DRocchi SRizzello ICangialosi CGaribaldi BFarina GIaccino EPetrucci MMele GfalseSurvival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsThe present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no differe2022-01-01T00:00:00Z2022 Jan2025-04-04T08:08:24.013Z2024-11-21T09:50:03.265ZS-EPMC9341470